Development of dividable one-step dry-coated tablets (dividable-OSDRC) and their evaluation as a new platform for controlled drug release
The purpose of this study is to develop novel dividable coated tablets that retain their characteristics even after they are divided. We prepared dividable one-step dry-coated tablets (dividable-OSDRC) using our own manufacturing process with double structure punches. The release pattern of the divi...
Saved in:
Published in | Pharmaceutical research Vol. 21; no. 7; pp. 1177 - 1183 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
Springer Nature B.V
01.07.2004
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The purpose of this study is to develop novel dividable coated tablets that retain their characteristics even after they are divided.
We prepared dividable one-step dry-coated tablets (dividable-OSDRC) using our own manufacturing process with double structure punches. The release pattern of the dividable-OSDRC with hydroxypropyl methylcellulose (HPMC) or methacrylic acid copolymer LD (Eudragit) as an outer layer was investigated before and after the division, and dissolution profiles were statistically compared using difference factor f1 and similarity factor f2.
The dividable-OSDRC with HPMC for sustained-release (compression pressure, 150 MPa; crashing strength, 6.1 N; friability, 0.05%; CV of divided tablet weight, 7.8%) showed statistically equivalent release patterns between the one-half and the whole (f1, 13.9; f2, 55.5) and between the one-half and the two-halves (5.5, 72.5). The surface area of the tablets affected the sustained-release profiles. Furthermore, the tablets made with Eudragit LD for timed-release (150 MPa. 12.8 N, 0.18%, 9.6%) also showed approximated release patterns before and after the division.
We proved that dividable-OSDRC maintain their release characteristics after they are divided. We conclude that the dividable-OSDRC could be used as a new platform for the controlled release of drugs. |
---|---|
AbstractList | The purpose of this study is to develop novel dividable coated tablets that retain their characteristics even after they are divided. We prepared dividable one-step dry-coated tablets (dividable-OSDRC) using our own manufacturing process with double structure punches. The release pattern of the dividable-OSDRC with hydroxypropyl methylcellulose (HPMC) or methacrylic acid copolymer LD (Eudragit) as an outer layer was investigated before and after the division, and dissolution profiles were statistically compared using difference factor f1 and similarity factor f2. The dividable-OSDRC with HPMC for sustained-release (compression pressure, 150 MPa; crashing strength, 6.1 N; friability, 0.05%; CV of divided tablet weight, 7.8%) showed statistically equivalent release patterns between the one-half and the whole (f1, 13.9; f2, 55.5) and between the one-half and the two-halves (5.5, 72.5). The surface area of the tablets affected the sustained-release profiles. Furthermore, the tablets made with Eudragit LD for timed-release (150 MPa. 12.8 N, 0.18%, 9.6%) also showed approximated release patterns before and after the division. We proved that dividable-OSDRC maintain their release characteristics after they are divided. We conclude that the dividable-OSDRC could be used as a new platform for the controlled release of drugs. PURPOSEThe purpose of this study is to develop novel dividable coated tablets that retain their characteristics even after they are divided. METHODSWe prepared dividable one-step dry-coated tablets (dividable-OSDRC) using our own manufacturing process with double structure punches. The release pattern of the dividable-OSDRC with hydroxypropyl methylcellulose (HPMC) or methacrylic acid copolymer LD (Eudragit) as an outer layer was investigated before and after the division, and dissolution profiles were statistically compared using difference factor f1 and similarity factor f2. RESULTSThe dividable-OSDRC with HPMC for sustained-release (compression pressure, 150 MPa; crashing strength, 6.1 N; friability, 0.05%; CV of divided tablet weight, 7.8%) showed statistically equivalent release patterns between the one-half and the whole (f1, 13.9; f2, 55.5) and between the one-half and the two-halves (5.5, 72.5). The surface area of the tablets affected the sustained-release profiles. Furthermore, the tablets made with Eudragit LD for timed-release (150 MPa. 12.8 N, 0.18%, 9.6%) also showed approximated release patterns before and after the division. CONCLUSIONSWe proved that dividable-OSDRC maintain their release characteristics after they are divided. We conclude that the dividable-OSDRC could be used as a new platform for the controlled release of drugs. The purpose of this study is to develop novel dividable coated tablets that retain their characteristics even after they are divided. We prepared dividable one-step dry-coated tablets (dividable-OSDRC) using our own manufacturing process with double structure punches. The release pattern of the dividable-OSDRC with hydroxypropyl methylcellulose (HPMC) or methacrylic acid copolymer LD (Eudragit) as an outer layer was investigated before and after the division, and dissolution profiles were statistically compared using difference factor f1 and similarity factor f2. The dividable-OSDRC with HPMC for sustained-release (compression pressure, 150 MPa; crashing strength, 6.1 N; friability, 0.05%; CV of divided tablet weight, 7.8%) showed statistically equivalent release patterns between the one-half and the whole (f1, 13.9; f2, 55.5) and between the one-half and the two-halves (5.5, 72.5). The surface area of the tablets affected the sustained-release profiles. Furthermore, the tablets made with Eudragit LD for timed-release (150 MPa. 12.8 N, 0.18%, 9.6%) also showed approximated release patterns before and after the division. We proved that dividable-OSDRC maintain their release characteristics after they are divided. We conclude that the dividable-OSDRC could be used as a new platform for the controlled release of drugs. |
Author | Ozeki, Yuichi Okamoto, Hirokazu Danjo, Kazumi Watanabe, Yukinao |
Author_xml | – sequence: 1 givenname: Yuichi surname: Ozeki fullname: Ozeki, Yuichi email: yu_ozeki@skk-net.com organization: Pharmaceutical Research & Technology Laboratory, Sanwa Kagaku Kenkyusho Co. Ltd., Gifu-City, Japan. yu_ozeki@skk-net.com – sequence: 2 givenname: Yukinao surname: Watanabe fullname: Watanabe, Yukinao – sequence: 3 givenname: Hirokazu surname: Okamoto fullname: Okamoto, Hirokazu – sequence: 4 givenname: Kazumi surname: Danjo fullname: Danjo, Kazumi |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15290857$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkc1u1DAQgC1URLeFV0BWDwgOWWzHjuPe2m2hSEVF_EjcLMcZQyonDrazqI_AW9dLV1TCh_FhvvnRfEfoYAoTIHRCyZoSVr89P_10dfZxTXavrgnh67ZVol539glaUSHrShH-_QCtiGS8aiWnh-gopduCt1TxZ-iQCqZIK-QK_bmALfgwjzBlHBzuh-3Qm84DLjOrlGHGfbyrbDAZepx3mZzw639YdfPl4vPmDTZTyf6EIWLYGr-YPIQJm4QNnuA3nr3JLsQRl4BtmHIM3pd-fVx-4AgeTILn6KkzPsGL_X-Mvr27_Lq5qq5v3n_YnF1XtuYsV9RyBcZZ1QjqGiplrxwHxjohWycYbUAKx4iVIKEVVIBsa0agVs4SZ8rBjtGrh75zDL8WSFmPQ7LgvZkgLEk3jWwkV7SAJ_-Bt2GJU9lNM8YkKSpkgU4fIBtDShGcnuMwmninKdE7W_pc72zpR1v6ry3d2VL8cj9h6UboH0v3eup7rESUOQ |
CitedBy_id | crossref_primary_10_1248_yakushi_128_951 crossref_primary_10_1016_j_jconrel_2011_09_065 crossref_primary_10_1016_j_ijpharm_2006_12_015 crossref_primary_10_1248_yakushi_127_2057 crossref_primary_10_2174_1381612829666230423144232 crossref_primary_10_1016_j_heliyon_2024_e29064 crossref_primary_10_1016_j_ijpharm_2006_11_042 crossref_primary_10_1016_j_jsps_2011_08_003 crossref_primary_10_4161_biom_1_1_17717 crossref_primary_10_1007_s11095_007_9315_3 crossref_primary_10_1080_10837450701212479 crossref_primary_10_4236_ojs_2012_23032 |
ContentType | Journal Article |
Copyright | Copyright Kluwer Academic Publishers Jul 2004 |
Copyright_xml | – notice: Copyright Kluwer Academic Publishers Jul 2004 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7RV 7TK 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PQEST PQQKQ PQUKI PRINS 7X8 |
DOI | 10.1023/B:PHAM.0000033004.88953.bc |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) ProQuest Nursing and Allied Health Journals Neurosciences Abstracts Health Medical collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland AUTh Library subscriptions: ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection Neurosciences Abstracts ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest One Academic Eastern Edition MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1573-904X |
EndPage | 1183 |
ExternalDocumentID | 679245101 10_1023_B_PHAM_0000033004_88953_bc 15290857 |
Genre | Journal Article |
GroupedDBID | --- -4W -56 -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 123 199 1N0 1SB 2.D 203 28- 29O 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3SX 3V. 4.4 406 408 409 40D 40E 53G 5QI 5VS 67N 67Z 6NX 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAEOY AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAQLM AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYOK AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACIPQ ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYPR ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BPHCQ BVXVI CAG CCPQU CGR COF CS3 CSCUP CUY CVF DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS ECM EIF EIOEI EJD EMOBN EN4 EPAXT ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO IHE IJ- IKXTQ IMOTQ INH ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAK LLZTM LSO M1P M4Y MA- MK0 N2Q N9A NAPCQ NB0 NDZJH NPM NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TEORI TSG TSK TSV TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK6 WK8 WOW YCJ YLTOR Z45 Z5O Z7S Z7U Z7V Z7W Z7X Z81 Z82 Z83 Z84 Z87 Z88 Z8N Z8O Z8P Z8Q Z8R Z8V Z8W Z91 Z92 ZGI ZMTXR ZOVNA ~KM AAYXX ADOAH CITATION 7TK 7XB 8FK K9. PQEST PQUKI PRINS 7X8 |
ID | FETCH-LOGICAL-c342t-1c49eafc9651f6177d9f4e22b578f5216e75f20c7e7e8515e78320e39fc0fa003 |
IEDL.DBID | BENPR |
ISSN | 0724-8741 |
IngestDate | Fri Oct 25 21:32:43 EDT 2024 Thu Oct 10 16:09:36 EDT 2024 Thu Sep 12 18:55:30 EDT 2024 Wed Oct 16 00:51:23 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c342t-1c49eafc9651f6177d9f4e22b578f5216e75f20c7e7e8515e78320e39fc0fa003 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 15290857 |
PQID | 222700237 |
PQPubID | 37334 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_66767491 proquest_journals_222700237 crossref_primary_10_1023_B_PHAM_0000033004_88953_bc pubmed_primary_15290857 |
PublicationCentury | 2000 |
PublicationDate | 2004-Jul 2004-07-00 20040701 |
PublicationDateYYYYMMDD | 2004-07-01 |
PublicationDate_xml | – month: 07 year: 2004 text: 2004-Jul |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: New York |
PublicationTitle | Pharmaceutical research |
PublicationTitleAlternate | Pharm Res |
PublicationYear | 2004 |
Publisher | Springer Nature B.V |
Publisher_xml | – name: Springer Nature B.V |
SSID | ssj0008194 |
Score | 1.8401837 |
Snippet | The purpose of this study is to develop novel dividable coated tablets that retain their characteristics even after they are divided.
We prepared dividable... The purpose of this study is to develop novel dividable coated tablets that retain their characteristics even after they are divided. We prepared dividable... PURPOSEThe purpose of this study is to develop novel dividable coated tablets that retain their characteristics even after they are divided. METHODSWe prepared... |
SourceID | proquest crossref pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 1177 |
SubjectTerms | Acetaminophen - chemistry Chemical Phenomena Chemistry, Pharmaceutical Chemistry, Physical Compressive Strength Delayed-Action Preparations - chemistry Drug Compounding Drug dosages Excipients - chemistry Hypromellose Derivatives Kinetics Manufacturing Methylcellulose - analogs & derivatives Methylcellulose - chemistry Solubility Tablets, Enteric-Coated - chemistry Time Factors |
Title | Development of dividable one-step dry-coated tablets (dividable-OSDRC) and their evaluation as a new platform for controlled drug release |
URI | https://www.ncbi.nlm.nih.gov/pubmed/15290857 https://www.proquest.com/docview/222700237 https://search.proquest.com/docview/66767491 |
Volume | 21 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9MwFLdYd-GCYHyVwfYOaAJpZo0_6oULWj-mCmlbVDqpN8txbIQ0JaNJD_0T-K95TtKUHcYlF0e25Pdpv9_7mZCPits4i6KUSuM8Fdw7em4soyLjRlo-zM7rq-yr6-HsVnxfymWLzSlbWOXWJ9aOOitsuCM_Cz2bIcCob_e_aXg0KhRX2xc09sg-w4MC65H90fQ6mXeuGMNdzR-lmECzF9GWdZTxs9HXZHZx1dIXBtopVJlY8i-pfRihHkk76_Bz-Zw8a_NGuGgE_YI8cfkBOUka4unNKSx2fVTlKZxAsqOk3rwkf_7BBkHhYRKasELTFNzkjgakF0xWGzouMPPMYBFGqhI-db_Rmx-T-fgzmDwLK_1awbRjCQdTggF0lpDcmSrkwIAfGDcY-Ducb7Ja_4Q5xjeMmK_I7eV0MZ7R9hEGarlgFY2siJ3xNh7KyGO6o7LYC8dYiqbuMfYPnZKeDaxyymH2Jp1CHzFwPPZ24A3u7WvSy4vcvSXArFVMOm-4zYRzKrWoFjKN2MCHYmnUJ3y78fq-4drQdY2ccT3SQVx6Jy5di0untk8OtzLSrf2VutOWPjnuRtFwQjXE5K5YlzqAe5WIcdU3jWB3a0oWB-L_d_-d-ZA8bVA8Abr7nvSq1dp9wASlSo_Inlqqo1YZ_wIUqeOM |
link.rule.ids | 315,783,787,12070,21402,27938,27939,31733,31734,33758,33759,43324,43819,74081,74638 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NT9swFLcYHLbLtLEPCtt4hwltEh6NP2rCZYIW1G0UKlak3izHsScklLAmPfRP2H-NX5KmcGCXXBzZkt-n_X7vZ0I-K27jNIoSKo3zVHDv6KGxjIqUG2l5Lz2srrJHF73htfg5ldMGm1M0sMqlT6wcdZpbvCM_wJ5NDDDq-91fio9GYXG1eUHjGdlAGi6kzlfT9ryFwa5ij1JMBKMX0ZJzlPGDk6Px8HjUkBci6VRQmFjyb4l9HJ-eSDqr4HP2irxsskY4rsX8mqy5bJPsjWva6cU-TFZdVMU-7MF4RUi9eEP-PUAGQe5hgC1Y2DIFl5mjiPOCwWxB-3nIO1OY4EhZwJf2N3r5e3DV_womS3GlmxmcthzhYAowEFwljG9NiRkwhA_0awT8bZhvMJv_gasQ3UK8fEuuz04n_SFtnmCglgtW0siK2Blv456MfEh2VBp74RhLgqH7EPl7TknPulY55ULuJp0KHqLreOxt15uwt-_IepZnbosAs1Yx6bzhNhXOqcQGpZBJxLoeS6VRh_Dlxuu7mmlDVxVyxvWJRnHplbh0JS6d2A7ZWcpIN9ZX6FZXOmS3HQ1mg7UQk7l8XmiE9ioRh1Xf14JdrSlZjLT_2_-deZc8H05G5_r8x8WvHfKixvMgiPcDWS9nc_cxpCpl8qlSyHu1MeQw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4s22QOeAKpBqduPHuuGC2k1Xy6NtVLbS3izHsRFSlbSb7GF_Av-acZLNwgEuuTiyJc945kv8zTeEvFXcxnkUZVQa56ng3tEjYxkVOTfS8nF-1PzKPjsfz67El4VcdJJCVUer3MTEJlDnpQ3_yIehZjMkGDX0HSsiTaafbm5paCAVLlq7bhp3yT0lMM-ha6tF_-0VEl-jJKWYwAAgoo3-KOPDk4_p7PisEzIMAlToPLHkHzL7d676BwBtEtH0EXnYIUg4bk3-mNxxxRNykLYS1OtDmG8rqqpDOIB0K069fkp-_cESgtJDEsqxQvkUXBSOBs4XJMs1nZSIQXOYh5G6gnf9a_Tie3I5eQ-myMNKP5dw2uuFg6nAAIZNSK9NHdAw4AMmLRv-GudLlqsfcImZDnPnM3I1PZ1PZrRrx0AtF6ymkRWxM97GYxl5BD4qj71wjGV46D2igLFT0rORVU45xHHSKYwWI8djb0fe4N4-JztFWbiXBJi1iknnDbe5cE5lFh1EZhEb-XBtGg0I32y8vmlVN3RzW864PtHBXHprLt2YS2d2QPY2NtLdSax07zcDst-P4hEK9yKmcOWq0oHmq0SMq75oDbtdU7I4tADY_e_M--Q--qL-9vn86x550FJ7Ap_3Fdmplyv3GlFLnb1p_PE3f8noZQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+Dividable+One-Step+Dry-Coated+Tablets+%28Dividable-OSDRC%29+and+Their+Evaluation+as+a+New+Platform+for+Controlled+Drug+Release&rft.jtitle=Pharmaceutical+research&rft.au=Ozeki%2C+Yuichi&rft.au=Watanabe%2C+Yukinao&rft.au=Okamoto%2C+Hirokazu&rft.au=Danjo%2C+Kazumi&rft.date=2004-07-01&rft.issn=0724-8741&rft.volume=21&rft.issue=7&rft.spage=1177&rft.epage=1183&rft_id=info:doi/10.1023%2FB%3APHAM.0000033004.88953.bc&rft.externalDBID=n%2Fa&rft.externalDocID=10_1023_B_PHAM_0000033004_88953_bc |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0724-8741&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0724-8741&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0724-8741&client=summon |